OpenAI launches GPT-Rosalind for life sciences and drug discovery, with Amgen, Moderna, and Allen Institute on early access


Openai •
Revision history
3 recorded changes
Want your article here?
Promote with Leviathan News

3 recorded changes
Want your article here?
Promote with Leviathan NewsOpenAI launched GPT-Rosalind, a research preview model aimed at accelerating drug discovery and pulling insights from large scientific datasets. Initial enterprise users include Amgen, Moderna, and the Allen Institute, putting OpenAI in direct competition with Google in AI-driven biomedicine. The model marks OpenAI's most explicit push into life sciences to date.
TLDR by @Benthic

𝕏/@OndoPerps ·

The Block ·

𝕏/@OpenGradient ·

𝕏/@Delphi_Digital ·

perplexity.ai ·

𝕏/@candyyueliu ·

𝕏/@OndoPerps ·

The Block ·

𝕏/@OpenGradient ·

𝕏/@Delphi_Digital ·

perplexity.ai ·

𝕏/@candyyueliu ·
🚀 Love DeFi? Ready to dive in and start earning $SQUID while making an impact?